Health & Fitness
Thu, October 27, 2011Wed, October 26, 2011Tue, October 25, 2011Mon, October 24, 2011Sat, October 22, 2011Fri, October 21, 2011Thu, October 20, 2011Wed, October 19, 2011Tue, October 18, 2011Mon, October 17, 2011Sun, October 16, 2011Sat, October 15, 2011Fri, October 14, 2011Thu, October 13, 2011Wed, October 12, 2011Alnylam to Webcast Presentation at the Newsmakers in the Biotech Industry 2011 Conference
//health-fitness.news-articles.net/content/2011/ .. ers-in-the-biotech-industry-2011-conference.html
Published in Health and Fitness on Thursday, October 20th 2011 at 5:49 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Newsmakers in the Biotech Industry 2011 Conference on Friday, October 21, 2011 at 10:30 a.m. ET at The Millennium Broadway Hotel in New York.
A live audio webcast of the presentation will be available on the aInvestorsa section of the companya™s website, [ www.alnylam.com ]. A replay of the presentation will be available on the Alnylam website within 48 hours after the event.
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR), ALN-PCS for the treatment of severe hypercholesterolemia, ALN-HPN for the treatment of refractory anemia, and ALN-APC for the treatment of hemophilia. As part of its aAlnylam 5x15TMa strategy, the company expects to have five RNAi therapeutic products for genetically defined diseases in advanced stages of clinical development by the end of 2015. Alnylam has additional partner-based programs in clinical or development stages, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection, ALN-VSP for the treatment of liver cancers, and ALN-HTT for the treatment of Huntingtona™s disease. The companya™s leadership position on RNAi therapeutics and intellectual property have enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist. In addition, Alnylam and Isis co-founded Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics; Regulus has formed partnerships with GlaxoSmithKline and Sanofi. Alnylam has also formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for application in biologics manufacturing, including recombinant proteins and monoclonal antibodies. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 100 peer-reviewed papers, including many in the worlda™s top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, and Cell. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit [ www.alnylam.com ].
